News >

Rapid Advances in ALK+ and ROS1+ NSCLC Bring Forth New Challenges

Kristi Rosa
Published: Tuesday, Aug 13, 2019

Conor E. Steuer, MD

Conor E. Steuer, MD
The treatment of patients with non–small cell lung cancer (NSCLC) who have oncogenic rearrangements, such as ALK or ROS1, has rapidly advanced in recent years with the rise of second- and third-generation inhibitors, said Conor E. Steuer, MD. However, with that progress, sequencing questions have emerged as well as the challenge of acquired resistance.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x